Clinical trials: 2019-nCoV
2019-nCoV
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.
- Trial name
- NCT04270383
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Children's Hospital
COVID-19
Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19
This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days…
- Trial name
- NCT04536090
- Testing
- Isoquercetin (IQC-950AN)
- Sponsor
- Institut de Recherches Cliniques de Montreal
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
Coronavirus Infections, Pneumonia, Viral
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract.
- Trial name
- NCT04321278
- Testing
- Hydroxychloroquine + azithromycin, Hydroxychloroquine
- Where
- 58 sites in Brazil
- Volunteers
- 440 people
- Sponsor
- Hospital Israelita Albert Einstein
Sars-CoV2, Symptomatic Condition
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine…
- Conditions
- Sars-CoV2, Symptomatic Condition, Covid-19
- Trial name
- PRECISE (NCT04351191)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 4 sites in Pakistan
- Volunteers
- 137 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
Long COVID, Long Coronavirus Disease 2019 (Covid19)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Trial name
- NCT06305793
- Testing
- IVIG (intravenous immunoglobulin), Coordinated Care, Usual Care
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Kanecia Obie Zimmerman
2019-nCoV, Immunoglobulin of Cured Patients
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug.
- Trial name
- NCT04264858
- Testing
- Immunoglobulin of cured patients, γ-Globulin
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.
- Trial name
- NCT04523571
- Testing
- BNT162b1
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
CT Scores Predict Mortality in 2019-nCoV Pneumonia
CT Scores Predict Mortality in 2019-nCoV Pneumonia
While 2019-nCoV nucleic acid swab tests has high false positives rate, How to diagnose 2019-nCoV pneumonia and predict prognosis by CT is very important.In this retrospective single-center study, we consecutively included…
- Trial name
- NCT04284046
- Testing
- CT score
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
COVID-19
Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey
The coronavirus disease 2019 (COVID-19) pandemic required a rapid surge of healthcare capacity to face a growing number of critically ill patients.
- Trial name
- EDUCOVID (NCT04732858)
- Testing
- Cross sectional e-Survey on surgeons exposed to any educational intervention
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vitamin C, Pneumonia, Viral
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency.
- Conditions
- Vitamin C, Pneumonia, Viral, Pneumonia, Ventilator-Associated
- Trial name
- NCT04264533
- Testing
- VC, Sterile Water for Injection
- Where
- China
- Volunteers
- 56 people
- Sponsor
- ZhiYong Peng
Coronavirus Infection, COVID
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
Specific Aims: 1. The investigators will prospectively evaluate and analyze changes in the appearance of the lungs and heart through serial acquisition of focused point-of-care ultrasound images in a cohort of patients with or…
- Conditions
- Coronavirus Infection, COVID, Covid-19, SARS-CoV-2
- Trial name
- NCT04339998
- Testing
- Point-of-Care Ultrasonography (POCUS)
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Minnesota
Corona Virus Infection, Pregnancy Related
Characteristics of COVID-19 Infection Among PREGnant Women
In December 2019, Coronavirus infection (COVID-19) was identified as causing serious respiratory infection in humans. Initially COVID-19 was propagated by infected symptomatic individuals; currently the disease is disseminated by…
- Trial name
- CCOVID-PREG (NCT04398264)
- Testing
- COVID-19 positive via testing
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Inova Health Care Services
Covid-19, Pneumonia
The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19
The aim of this study is to evaluate the efficacy of pulmonary physiotherapy on respiratory functions in hospitalized patients with Novel Coronavirus 2019 pneumonia.
- Conditions
- Covid-19, Pneumonia, SARS Pneumonia
- Trial name
- NCT04357340
- Testing
- Pulmonary Physiotherapy Techniques
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Healthy Participants
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.
This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled [14C]PF-07321332 in healthy male participants following oral administration with…
- Trial name
- NCT05178654
- Testing
- [14C]PF-07321332
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019 (COVID-19)
Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19
SENTAD-COVID Study is an adaptive, prospective, multicentric, open-label, and randomized controlled clinical trial involving hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19) infection during the…
- Trial name
- SENTAD-COVID (NCT04473170)
- Testing
- Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC), COVID-19 standard care
- Where
- United Arab Emirates
- Volunteers
- 146 people
- Sponsor
- Abu Dhabi Stem Cells Center
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19)
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
This is an observational study in which data from people with cancer who had the Coronavirus disease 2019 (COVID-19) are collected and studied.
- Conditions
- Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
- Trial name
- ROCURS (NCT05594147)
- Testing
- Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506)
- Where
- United States
- Volunteers
- 4,103 people
- Sponsor
- Bayer
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.